Advertisement

Document › Details
Argen-X N.V. (Argenx). (8/9/18). "Press Release: Argenx to Present at 2018 Wedbush PacGrow Healthcare Conference". Breda & Ghent.
argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Company will present on Tuesday, August 14th at 1:20 p.m. ET at the 2018 Wedbush PacGrow Healthcare Conference in New York.
A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A replay of the webcast will be available for 90 days following the presentation.
About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and the three antibody engineering technologies are designed to enable the expansion of the therapeutic index of the company’s product candidates.
www.argenx.com
For further information, please contact:
Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Beth DelGiacco, VP Investor Relations (US)
+1 518 424 4980
bdelgiacco@argenx.com
Record changed: 2018-08-23 |
Advertisement

More documents for Argen-X (Argenx) (Group)
- [1] Argen-X N.V. (Argenx). (2/4/19). "Press Release: Argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology". Breda, Ghent & San Diego, CA....
- [2] Argen-X N.V. (Argenx). (12/3/18). "Press Release: Argenx Enters Exclusive Global Collaboration and License Agreement with Cilag GmbH International, an Affiliate of Janssen, for Cusatuzumab (ARGX-110)". Breda & Ghent....
- [3] Argen-X N.V. (Argenx). (12/3/18). "Press Release: Argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia". Breda & Ghent....
- [4] Argen-X N.V. (Argenx). (11/7/18). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda & Ghent....
- [5] Argen-X N.V. (Argenx). (11/1/18). "Press Release: Argenx Announces New Cusatuzumab (ARGX-110) AML Data in Abstracts Published in Connection with 60th American Society of Hematology Annual Meeting and Exposition". Breda & Ghent....
- [6] Bone Therapeutics S.A.. (10/29/18). "Press Release: Bone Therapeutics Announces Appointment of Linda Lebon as Chief Regulatory Officer". Gosselies....
- [7] Argen-X N.V. (Argenx). (10/9/18). "Press Release: Argenx Awarded €2.6 Million VLAIO Grant to Explore New Applications of ABDEG Technology". Breda & Ghent....
- [8] Argen-X N.V. (Argenx). (9/21/18). "Press Release: Argenx Announces Closing of U.S. Public Offering". Breda & Ghent....
- [9] Argen-X N.V. (Argenx). (9/19/18). "Press Release: Argenx Raises approximately $300.6 Million in Gross Proceeds in a U.S. Public Offering". Breda & Ghent....
- [10] Argen-X N.V. (Argenx). (9/17/18). "Press Release: Argenx Reports Positive Topline Results from Phase 2 Proof-of-Concept Trial of Efgartigimod in Primary Immune Thrombocytopenia". Breda & Ghent....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top